Antibody Binding to NKA Alpha Subunit Activation Sites
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with low sodium potassium ATPase (NKA) activity lack effective methods to selectively activate NKA, despite its crucial role in various biological processes, with no known drugs or compounds identified for this purpose in the past 50 years.
Innovation Solution
Development of pharmaceutical compositions and methods involving antibodies or small molecules that bind to specific activation sites on the alpha subunit of NKA, including amino acid sequences such as DVEDSYGQQWTYEQR, RSATEEEPPNDD, KRQPRNPKTDKLVNE, and HLLGIRETWDDRWIN, to increase NKA activity and treat associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs or compounds are used, then NKA activity remains unchanged, but the need for effective treatment of diseases associated with low NKA activity persists
Solution Approach 1:
The patent changes the molecular parameter of NKA by introducing antibodies that bind to specific epitopes on the NKA alpha-subunit, transforming the enzyme from a static target to a dynamically activatable structure. This parameter change enables selective activation of NKA activity without affecting other cellular processes.
Solution Approach 2:
The patent introduces antibodies as intermediary molecules that mediate between the therapeutic goal (increasing NKA activity) and the biological target (NKA enzyme). These antibodies serve as selective mediators that bind to specific epitopes and trigger conformational changes in NKA, enabling controlled activation without direct contact with the enzyme's active site.
2Reliability
If antibodies binding to NKA activation sites are used, then NKA activity increases, but the complexity of identifying and producing these antibodies increases
Solution Approach 1:
The patent segments the NKA alpha-subunit into distinct functional domains by identifying specific epitopes (such as DR region, H1-H2 domain, H5-H6 domain) that can be independently targeted. This segmentation allows for the development of specialized antibodies against discrete regions, simplifying the overall approach compared to attempting to modify the entire enzyme structure.
Solution Approach 2:
The patent performs preliminary identification and characterization of specific epitope sequences on the NKA alpha-subunit before antibody production. By pre-defining target regions with known amino acid sequences and functional properties, the patent streamlines subsequent antibody development and reduces the complexity of screening and validation processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described approach effectively increases NKA activity in cells and tissues, providing a therapeutic means to treat or prevent diseases like heart disease, diabetes, and other conditions associated with low NKA expression, by enhancing enzymatic activity and cardiac contraction.
Implementation Method 1
Sodium potassium ATPase (hereafter referred to as 'NKA') is an integral membrane protein that couples the hydrolysis of ATP to the vectorial transport of Na+ ions and K+ ions across the plasma membrane of all animal cells
Data Source
AI summary
Activation sites on the alpha subunit of sodium potassium ATPase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium ATPase dramatically increase enzyme activity. There has never before been a report of precise activation sites or drug interaction sites for sodium potassium ATPase. Certain methods have also been discovered for treating or preventing diseases associated with low sodium potassium ATPase activity by administering antibodies, antibody fragments and small molecules that bind to the activation sites on the alpha subunit of sodium potassium ATPase.